当前位置：
X-MOL 学术
›
Arch. Med. Sci.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Differential expression of angiogenesis-related miRNAs and VEGFA in cirrhosis and hepatocellular carcinoma.
Archives of Medical Science ( IF 3.0 ) Pub Date : 2020-08-10 , DOI: 10.5114/aoms.2020.97967 André R C P de Oliveira 1, 2 , Márcia M U Castanhole-Nunes 1, 2 , Patrícia M Biselli-Chicote 1 , Érika C Pavarino 1 , Rita de C M A da Silva 2 , Renato F da Silva 2 , Eny M Goloni-Bertollo 1, 2
Archives of Medical Science ( IF 3.0 ) Pub Date : 2020-08-10 , DOI: 10.5114/aoms.2020.97967 André R C P de Oliveira 1, 2 , Márcia M U Castanhole-Nunes 1, 2 , Patrícia M Biselli-Chicote 1 , Érika C Pavarino 1 , Rita de C M A da Silva 2 , Renato F da Silva 2 , Eny M Goloni-Bertollo 1, 2
Affiliation
Introduction
Liver cirrhosis (LC) is a heterogeneous liver disease, the last stage of liver fibrosis, and the major risk factor for hepatocellular carcinoma (HCC). Our study aimed to evaluate the expression of microRNAs and the endothelial vascular growth factor (VEGFA) gene in LC and HCC.
Material and methods
The sample group consisted of 46 tissue samples: 21 of LC, 15 of HCC, and 10 of non-tumoural and non-cirrhotic liver tissue (control group). MiRNAs were chosen based on a mirDIP prediction database as regulators of the VEGFA gene. Gene expression of VEGF and miRNAs was quantified by real-time quantitative polymerase chain reaction. VEGFA protein expression was evaluated by ELISA.
Results
VEGFA gene expression was significantly overexpressed in LC compared to the control group (p < 0.0001). Hsa-miR-206 (p = 0.0313) and hsa-miR-637 (p = 0.0156) were down-expressed in LC. In HCC, hsa-miR-15b (p = 0.0010), hsa-miR-125b (p = 0.0010), hsa-miR-423-3p (p = 0.0010), hsa-miR-424 (p = 0.0313), hsa-miR-494 (p < 0.0001), hsa-miR-497 (p < 0.0001), hsa-miR-612 (p = 0.0078), hsa-miR-637 (p < 0.0001), and hsa-miR-1255b (p = 0.0156) presented down-expression.
Conclusions
Overexpression of VEGFA in LC suggests impairment of angiogenesis in this tissue. The differential expression of microRNAs in LC and HCC observed in our study can lead to the evaluation of possible biomarkers for these diseases.
中文翻译：
血管生成相关 miRNA 和 VEGFA 在肝硬化和肝细胞癌中的差异表达。
简介
肝硬化 (LC) 是一种异质性肝病，是肝纤维化的最后阶段，是肝细胞癌 (HCC) 的主要危险因素。我们的研究旨在评估 LC 和 HCC 中 microRNA 和内皮血管生长因子 (VEGFA) 基因的表达。
材料与方法
样本组由 46 份组织样本组成：21 份 LC，15 份 HCC，10 份非肿瘤和非肝硬化肝组织（对照组）。基于 mirDIP 预测数据库选择 miRNA 作为 VEGFA 基因的调节因子。通过实时定量聚合酶链反应对 VEGF 和 miRNA 的基因表达进行量化。通过ELISA评估VEGFA蛋白表达。
结果
与对照组相比，VEGFA 基因表达在 LC 中显着过表达（p < 0.0001）。Hsa-miR-206 (p = 0.0313) 和 hsa-miR-637 (p = 0.0156) 在 LC 中下调。在 HCC 中，hsa-miR-15b (p = 0.0010)、hsa-miR-125b (p = 0.0010)、hsa-miR-423-3p (p = 0.0010)、hsa-miR-424 (p = 0.0313)、hsa -miR-494 (p < 0.0001)、hsa-miR-497 (p < 0.0001)、hsa-miR-612 (p = 0.0078)、hsa-miR-637 (p < 0.0001) 和 hsa-miR-1255b ( p = 0.0156) 呈现下调。
结论
LC 中 VEGFA 的过表达表明该组织中的血管生成受损。在我们的研究中观察到的 LC 和 HCC 中 microRNA 的差异表达可以导致评估这些疾病的可能生物标志物。
更新日期：2020-08-20
Liver cirrhosis (LC) is a heterogeneous liver disease, the last stage of liver fibrosis, and the major risk factor for hepatocellular carcinoma (HCC). Our study aimed to evaluate the expression of microRNAs and the endothelial vascular growth factor (VEGFA) gene in LC and HCC.
Material and methods
The sample group consisted of 46 tissue samples: 21 of LC, 15 of HCC, and 10 of non-tumoural and non-cirrhotic liver tissue (control group). MiRNAs were chosen based on a mirDIP prediction database as regulators of the VEGFA gene. Gene expression of VEGF and miRNAs was quantified by real-time quantitative polymerase chain reaction. VEGFA protein expression was evaluated by ELISA.
Results
VEGFA gene expression was significantly overexpressed in LC compared to the control group (p < 0.0001). Hsa-miR-206 (p = 0.0313) and hsa-miR-637 (p = 0.0156) were down-expressed in LC. In HCC, hsa-miR-15b (p = 0.0010), hsa-miR-125b (p = 0.0010), hsa-miR-423-3p (p = 0.0010), hsa-miR-424 (p = 0.0313), hsa-miR-494 (p < 0.0001), hsa-miR-497 (p < 0.0001), hsa-miR-612 (p = 0.0078), hsa-miR-637 (p < 0.0001), and hsa-miR-1255b (p = 0.0156) presented down-expression.
Conclusions
Overexpression of VEGFA in LC suggests impairment of angiogenesis in this tissue. The differential expression of microRNAs in LC and HCC observed in our study can lead to the evaluation of possible biomarkers for these diseases.
中文翻译：
血管生成相关 miRNA 和 VEGFA 在肝硬化和肝细胞癌中的差异表达。
简介
肝硬化 (LC) 是一种异质性肝病，是肝纤维化的最后阶段，是肝细胞癌 (HCC) 的主要危险因素。我们的研究旨在评估 LC 和 HCC 中 microRNA 和内皮血管生长因子 (VEGFA) 基因的表达。
材料与方法
样本组由 46 份组织样本组成：21 份 LC，15 份 HCC，10 份非肿瘤和非肝硬化肝组织（对照组）。基于 mirDIP 预测数据库选择 miRNA 作为 VEGFA 基因的调节因子。通过实时定量聚合酶链反应对 VEGF 和 miRNA 的基因表达进行量化。通过ELISA评估VEGFA蛋白表达。
结果
与对照组相比，VEGFA 基因表达在 LC 中显着过表达（p < 0.0001）。Hsa-miR-206 (p = 0.0313) 和 hsa-miR-637 (p = 0.0156) 在 LC 中下调。在 HCC 中，hsa-miR-15b (p = 0.0010)、hsa-miR-125b (p = 0.0010)、hsa-miR-423-3p (p = 0.0010)、hsa-miR-424 (p = 0.0313)、hsa -miR-494 (p < 0.0001)、hsa-miR-497 (p < 0.0001)、hsa-miR-612 (p = 0.0078)、hsa-miR-637 (p < 0.0001) 和 hsa-miR-1255b ( p = 0.0156) 呈现下调。
结论
LC 中 VEGFA 的过表达表明该组织中的血管生成受损。在我们的研究中观察到的 LC 和 HCC 中 microRNA 的差异表达可以导致评估这些疾病的可能生物标志物。
京公网安备 11010802027423号